#1

Join in, if you live close to San Antonio:

Rapa-CV Substudy E

Effect of mTOR Inhibition and Other Metabolism Modulating Interventions on the Elderly: Immune, Cognitive, and Functional Consequences (Substudy E – RAPA cMRI with LGE)

Purpose of this Study

Rapamycin is a medication approved by the US Food and Drug Administration (FDA) as an immunosuppressant drug (a drug that reduces the human body’s normal immune response) used to prevent rejection in organ transplantation; it is especially useful in kidney transplants. Rapamycin reduces the effects of mTOR, which is a substance that controls growth of cells in your body. Rapamycin that has been shown to increase lifespan in laboratory animals.

The safety of Rapamycin in humans has been tested in prior research studies alone or in combination with another drug, to evaluate effects on physical function, cognitive function and immune health.

This new study will help find out what effects, Rapamycin has on people who take the drug and the drug’s effect on heart function, heart muscle stiffening, and other effects on circulation.

You may qualify if you:

  • Male
  • 70-95 years of age
  • A Non-smoker
  • In good general health
  • Able to tolerate MRI procedures
  • Living independently (not in assisted living or nursing home)

Details:

4 Likes
Too Much uncertainty?
#2

FWIW

Look up the testing procedures and copy.

#3

Here you go:

1mg/day po for 8 weeks, only 12 participants.

Seems TOO SHORT a time interval for dysregulation to resolve, although 1mg/day would likely be sub-therapeutic trough levels for SOME of the cohort.

Primary objectives are cardiac function, no lipids noted…but can they do a cardiac function trial without checking lipids?

Anyway, at least it’s human data at a decent dose!

4 Likes